In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly ...
Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year ...
Purple Biotech Ltd, a clinical-stage company developing first-in-class therapies that harness the power of the tumour microenvironment to overcome tumour immune evasion and drug resistance, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback